Product Data Sheet

Product Name: Panitumumab
Cat. No.: GC66405

Chemical Properties

Cas. No.	339177-26-3		
Formula		M.Wt	147kDa
Solubility		Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		
Structure			

Panitumumab

Background

Panitumumab (ABX-EGF) is a fully human IgG2 anti-**EGFR** monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4].

Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells [4].
Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].

Western Blot Analysis[3]

Cell Line:	EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration:	2, 20, 200, 2000 nM
Incubation Time:	3 h
Result:	Inhibited ligand-induced autophosphorylation of EGFR.

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control ($P < 0.0003$)[1].

Animal Model:	NCI-H1975 and NCI-H1650 xenografts[3]
Dosage:	25, 100, or 500 μg/mouse
Administration:	Intraperitoneal injection (i.p.), twice a week
Result:	Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.